Antidepressants to prevent relapse in depressio
- Conditions
- DepressionMental and Behavioural Disorders
- Registration Number
- ISRCTN15969819
- Lead Sponsor
- PRIMENT CTU, University College London
- Brief Summary
2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31159856 protocol (added 05/06/2019) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34587384/ results (added 30/09/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34748164/ Cost-Utility Analysis (added 10/11/2021) 2021 Funder report results in https://pubmed.ncbi.nlm.nih.gov/34842135/ (added 30/11/2021) 2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/36928675/ Substudy results (added 10/10/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 478
1. Aged between 18 and 74 years
2. Have experienced at least two episodes of depression
3. Have been taking antidepressants for at least 9 months (citalopram 20mg, sertraline 100mg, fluoxetine 20mg or mirtazapine 30mg)
4. Be well enough to consider stopping their antidepressant medication
Current exclusion criteria as of 27/09/2018:
1. Meet internationally agreed (ICD10) criteria for a depressive illness
2. Have bipolar disorder, psychotic illness, dementia or a terminal illness
3. Are not able to complete self-administered questionnaires in English
4. Have contraindications for any of the prescribed medication
5. Women who are currently pregnant or planning pregnancy or lactating
6. Concurrently enrolled in another investigational medicinal product (IMP) trial
Previous exclusion criteria:
1. Meet internationally agreed (ICD10) criteria for a depressive illness
2. Score above 10 on the depressive symptom questionnaire (PHQ9)
3. Have bipolar disorder, psychotic illness, dementia or a terminal illness
4. Are not able to complete self-administered questionnaires in English
5. Have contraindications for any of the prescribed medication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> Current primary outcome measure as of 27/09/2018:<br> Time to depressive relapse measured using the modified shortened clinical interview schedule-revised (CIS-R) at baseline, 6 weeks, 12 weeks, 26 weeks, 39 weeks and 52 weeks.<br><br> Previous primary outcome measure:<br> Time to depressive relapse measured using the modified shortened clinical interview schedule-revised (CIS-R) at baseline, 12 weeks, 26 weeks, 39 weeks and 52 weeks.<br>
- Secondary Outcome Measures
Name Time Method